Vivoryon Therapeutics N.V. (VVY.AS)

EUR 1.97

(0.71%)

Total Liabilities Summary of Vivoryon Therapeutics N.V.

  • Vivoryon Therapeutics N.V.'s latest annual total liabilities in 2023 was 4.54 Million EUR , down -6.67% from previous year.
  • Vivoryon Therapeutics N.V.'s latest quarterly total liabilities in 2024 Q2 was 3.01 Million EUR , down 0.0% from previous quarter.
  • Vivoryon Therapeutics N.V. reported annual total liabilities of 4.87 Million EUR in 2022, down -38.82% from previous year.
  • Vivoryon Therapeutics N.V. reported annual total liabilities of 7.96 Million EUR in 2021, up 125.58% from previous year.
  • Vivoryon Therapeutics N.V. reported quarterly total liabilities of 4.54 Million EUR for 2023 FY, down -6.67% from previous quarter.
  • Vivoryon Therapeutics N.V. reported quarterly total liabilities of 3.82 Million EUR for 2023 Q2, down 0.0% from previous quarter.

Annual Total Liabilities Chart of Vivoryon Therapeutics N.V. (2023 - 2010)

Historical Annual Total Liabilities of Vivoryon Therapeutics N.V. (2023 - 2010)

Year Total Liabilities Total Liabilities Growth
2023 4.54 Million EUR -6.67%
2022 4.87 Million EUR -38.82%
2021 7.96 Million EUR 125.58%
2020 3.53 Million EUR 10.45%
2019 3.19 Million EUR 113313.77%
2018 2818.00 EUR 53.24%
2017 1839.00 EUR -69.3%
2016 5990.00 EUR 4.48%
2015 5733.00 EUR 4.07%
2014 5509.00 EUR -99.95%
2013 10.59 Million EUR 128.41%
2012 4.64 Million EUR 11.86%
2011 4.14 Million EUR 11.3%
2010 3.72 Million EUR 0.0%

Peer Total Liabilities Comparison of Vivoryon Therapeutics N.V.

Name Total Liabilities Total Liabilities Difference
ABIONYX Pharma SA 6.91 Million EUR 34.216%
ABIVAX Société Anonyme 131.05 Million EUR 96.53%
Adocia SA 31.87 Million EUR 85.733%
Aelis Farma SA 13.08 Million EUR 65.237%
Biophytis S.A. 15.84 Million EUR 71.31%
Advicenne S.A. 24.37 Million EUR 81.347%
genOway Société anonyme 14.45 Million EUR 68.554%
IntegraGen SA 5.97 Million EUR 23.961%
Medesis Pharma S.A. 6.42 Million EUR 29.243%
Neovacs S.A. 3.71 Million EUR -22.491%
NFL Biosciences SA 3.62 Million EUR -25.584%
Plant Advanced Technologies SA 6.78 Million EUR 32.958%
Quantum Genomics Société Anonyme 3.31 Million EUR -37.367%
Sensorion SA 13.22 Million EUR 65.624%
Theranexus Société Anonyme 5.01 Million EUR 9.353%
TME Pharma N.V. 2.78 Million EUR -63.268%
Valbiotis SA 13.7 Million EUR 66.83%
TheraVet SA 1.48 Million EUR -206.197%
Valerio Therapeutics Société anonyme 20.46 Million EUR 77.785%
argenx SE 402.79 Million EUR 98.871%
BioSenic S.A. 32.26 Million EUR 85.907%
Celyad Oncology SA 9.97 Million EUR 54.43%
DBV Technologies S.A. 38.74 Million USD 88.264%
Galapagos NV 1.56 Billion EUR 99.709%
Genfit S.A. 105.92 Million EUR 95.707%
GeNeuro SA 20.13 Million EUR 77.423%
Hyloris Pharmaceuticals SA 8.61 Million EUR 47.202%
Innate Pharma S.A. 132.29 Million EUR 96.563%
Inventiva S.A. 101.59 Million EUR 95.524%
MaaT Pharma SA 22.46 Million EUR 79.76%
MedinCell S.A. 77.77 Million EUR 94.153%
Nanobiotix S.A. 95.74 Million EUR 95.251%
Onward Medical N.V. 25.69 Million EUR 82.306%
Oryzon Genomics S.A. 25.12 Million EUR 81.903%
OSE Immunotherapeutics SA 59.07 Million EUR 92.304%
Oxurion NV 19.73 Million EUR 76.961%
Pharming Group N.V. 228.28 Million EUR 98.008%
Poxel S.A. 53.9 Million EUR 91.564%
GenSight Biologics S.A. 34.72 Million EUR 86.906%
Transgene SA 26.51 Million EUR 82.853%
Financière de Tubize SA 123.65 Million EUR 96.323%
UCB SA 6.56 Billion EUR 99.931%
Valneva SE 341.14 Million EUR 98.667%